Antithrombotic therapies for stroke prevention

D. H. Solomon, R. G. Hart

Research output: Contribution to journalShort surveypeer-review

13 Scopus citations


Aspirin is the most widely used antiplatelet agent, reducing nonfatal ischemic stroke by 22%. There is increasing evidence that the efficacy of aspirin may vary with the etiologic subtype of stroke. Although the cost and side effects have limited the use of ticlopidine, patients who are intolerant of aspirin and those experiencing transient ischemic attack or stroke during aspirin therapy should be given ticlopidine. Patients with atrial fibrillation have a five-fold increased risk of stroke and require prophylactic therapy with warfarin or aspirin. Aspirin is less effective than warfarin in preventing atrial fibrillation-associated stroke, but the higher risk of hemorrhagic complications and frequent monitoring associated with warfarin must be considered. Clinical and echocardiographic predictors of increased thromboembolic risk in atrial fibrillation patients have been identified and may direct the treatment choice.

Original languageEnglish (US)
Pages (from-to)48-53
Number of pages6
JournalCurrent opinion in neurology
Issue number1
StatePublished - Jan 1 1994

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Antithrombotic therapies for stroke prevention'. Together they form a unique fingerprint.

Cite this